IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade

By M. Ayers, J. Lunceford, M. Nebozhyn, E. Murphy, A. Loboda, D. Kaufman, Andrew Albright, Jonathan D. Cheng, S. Kang, V. Shankaran and 5 more. Journal of Clinical Investigation, 2017

1,763 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/43120eca376614a844320d50ba42e8259797a48a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. W. Zou
2. Ilona Kryczek
3. Shuang Wei
4. Jing Wang
5. Lieping Chen
6. D. Pardoll

In Oncology

1. W. Zou
2. John N. Weinstein
3. J. Bellmunt
4. Jing Wang
5. Lieping Chen

Citations in the corpus

• Integrative molecular and clinical modeling of clinical outcomes to PD-1 blockade in metastatic melanoma patients (2019, neutral): “In two gene signatures 39,40 , genes were incorporated independently (i.e. weighted) into the published model, but neither the direction nor the coefficient was available, so these signatures were excluded from evaluation.”
• A Consensus Molecular Classification of Muscle-invasive Bladder Cancer (2019, methodology): “Studies integrating mRNA signatures with data on response to anti-PD1/PD-L1 therapies [19,31] have reported associations of antiPD1/PD-L1 response with high levels of CD8 + T cells, high interferon gamma signals, and low activity of the transforming growth factor-beta pathway.”